Navigation Links
Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
Date:11/20/2007

EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. ("NTI") (Nasdaq: NTII) today announced that it was notified on November 19, 2007 by The NASDAQ Stock Market that it has regained compliance with applicable NASDAQ Capital Market continued listing standards. Previously, the NASDAQ Listing Qualifications Department had notified NTI that it was not in compliance with the $35 million market value of listed securities continued listing requirement. NTI regained compliance following the closing on November 2, 2007 of its underwritten stock offering, in which it raised gross proceeds of $60 million and net proceeds of approximately $55 million through the offering and sale of 21,818,181 shares of common stock.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Neurobiological Technologies Reports Going Concern Qualification
2. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
3. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
4. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
5. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
6. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
7. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
8. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
9. Advanced technologies aim to transform the coaching of top athletes
10. Global Med Technologies(R) Extends Its Worldwide Outreach
11. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers ... Athletic Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence ... Athletic Trainers are acknowledged by their peers with accolades and highly prestigious awards. ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... campaign, “Humans With Vaginas.” The goal is to ignite conversation via social media ... care products. The brand has declared September “Humans with Vaginas” month, releasing a ...
(Date:9/20/2017)... ... 20, 2017 , ... The Centers for Medicare and Medicaid Services (CMS) stated ... to using only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments ... complimentary webinars on October 17, 2017 at 2 P.M. EST and uncover how ...
(Date:9/20/2017)... ... September 20, 2017 , ... Health & Safety Institute (HSI) is offering ... 24- and 40-Hour courses from now until November 30, 2017 to assist with the ... discounted prices to all businesses and government agencies – whether or not they will ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive ... he emotionally pens his aspirations and goals to better one’s life through God. “The ... Green, while searching in all the wrong places, found a love for writing. Green ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/6/2017)... 2017 NeuroRx, a clinical stage biopharma company developing ... (ASIB), has been granted Fast Track status by the US ... (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company ... this sequential therapy targeting patients who are admitted to Emergency ... ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and Scannerside ... solution. Scannerside DoseCheck is a third-party Vendor neutral CT ... scanners and allows compliance with current MITA standards. ... XR 29 DoseCheck solution is specifically designed to provide ... of potential radiation doses over a predefined threshold. Scannerside ...
Breaking Medicine Technology: